6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003623-37-GB (EUCTR) | 12/02/2020 | 02/01/2020 | CANnabidiol for Parkinson’s Disease Psychosis | CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP | Parkinson's disease psychosis MedDRA version: 20.0;Level: PT;Classification code 10074835;Term: Parkinson's disease psychosis;System Organ Class: 10037175 - Psychiatric disorders;Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02] | Product Name: Cannabidiol Product Code: Cannabidiol INN or Proposed INN: Cannabidiol (CBD) | King's College London | South London and Maudsley NHS Foundation Trust | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 144 | Phase 2 | United Kingdom | ||
| 2 | NCT03582137 (ClinicalTrials.gov) | September 17, 2018 | 17/4/2018 | A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease | Parkinson Disease | Drug: Cannabidiol;Other: Placebo | University of Colorado, Denver | Colorado Department of Public Health and Environment | Completed | 40 Years | 85 Years | All | 74 | Phase 2 | United States |
| 3 | NCT02818777 (ClinicalTrials.gov) | October 2016 | 6/5/2016 | A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease | Parkinson's Disease | Drug: cannabidiol | University of Colorado, Denver | Colorado Department of Public Health and Environment;GW Research Ltd | Completed | 40 Years | 80 Years | All | 13 | Phase 2 | United States |